Tianjin Zhong Xin Pharmaceutical Group Corporation Limited (2TZ) — Capital Reinvestment Ratio
Tianjin Zhong Xin Pharmaceutical Group Corporation Limited (2TZ) has a Capital Reinvestment Ratio of 0.24x as of March 2023, meaning it reinvests 0% of its operating cash flow (€186.97 Million) in capital expenditures (€44.48 Million). See 2TZ free cash flow to operating cash ratio to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Tianjin Zhong Xin Pharmaceutical Group Corporation Limited Capital Reinvestment Ratio (2013–2025)
This chart tracks Tianjin Zhong Xin Pharmaceutical Group Corporation Limited's Capital Reinvestment Ratio across 12 annual periods.
Annual Capital Reinvestment Ratio for Tianjin Zhong Xin Pharmaceutical Group Corporation Limited (2013–2025)
Year-by-year Capital Reinvestment Ratio for Tianjin Zhong Xin Pharmaceutical Group Corporation Limited from 2013 to 2025. For live market cap and broader valuation context, see Tianjin Zhong Xin Pharmaceutical Group C market cap and net worth.
| Year | Reinvestment Ratio | Operating CF (EUR) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.26x | €461.07 Million | €118.61 Million | ▲ +101.9% |
| 2024 | 0.13x | €924.67 Million | €117.81 Million | ▼ -37.8% |
| 2023 | 0.20x | €688.49 Million | €140.93 Million | ▲ +28.5% |
| 2022 | 0.16x | €677.25 Million | €107.90 Million | ▼ -13.5% |
| 2021 | 0.18x | €852.40 Million | €156.95 Million | ▼ -34.6% |
| 2020 | 0.28x | €671.42 Million | €189.16 Million | ▼ -32.1% |
| 2019 | 0.41x | €495.49 Million | €205.61 Million | ▼ -17.4% |
| 2018 | 0.50x | €350.14 Million | €175.81 Million | ▲ +80.5% |
| 2016 | 0.28x | €417.77 Million | €116.20 Million | ▲ +8.3% |
| 2015 | 0.26x | €360.58 Million | €92.64 Million | ▲ +5.1% |
| 2014 | 0.24x | €286.85 Million | €70.15 Million | ▼ -27.9% |
| 2013 | 0.34x | €213.44 Million | €72.42 Million | — |